24 May 2017 - Scott Gottlieb, the Trump administration's FDA commissioner, generally gets a big thumbs-up from the pharmaceutical industry. 

But he may end up making some drugmakers unhappy.An ex-FDA official, physician, industry consultant, and biotech investor, Gottlieb is seen as industry friendly and was certainly preferable to some other less experienced and more extreme candidates the White House floated. 

But he seems to have a mandate that includes getting drug prices under control -- a topic he mentioned in his initial remarks to FDA staff on May 15. President Donald Trump, meanwhile, has gone from terrifying the pharma industry with pricing criticism to increasingly conspicuous silence. A White House budget plan released Tuesday essentially ignored drug pricing.

Read Bloomberg Gadfly article